[177Lu]Lu-PEP49989 affibody shows antitumor efficacy in preclinical ovarian cancer
Oct. 28, 2024
The advantages of affibodies vs. antibodies are that they have a smaller size, better penetration and faster extravasation, can be produced both recombinantly and synthetically, and show robustness regarding protein scaffold.